FDA Opens Botanical Drug Docket as Appalachia’s Wild Ginseng Season Gets Underway Under Federal Trade Controls
Nature World News | 08.09.2026 04:00
The Food and Drug Administration opened a public docket on September 4, seeking input on how to accelerate the development of botanical drug products, which the agency defines as drug products that include or may be derived from plant material, algae, macroscopic fungi, or combinations of them. Comments are due by 11:59 p.m. Eastern on November 3, 2026.
